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Abstract
To convince policy-makers or funders of health care of the value of orthopaedic interventions, we need to consider value for 
money (cost-effectiveness), as well as clinical effectiveness. This article provides an introduction to health economics to set 
the scene for papers on the use of allografts in the knee.
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Abbreviations
HTA  Health technology assessment
QALY  Quality-adjusted life year
ACI  Autologous chondrocyte implantation
EQ-5D  The EuroQol measure of quality of life
Introduction
The four papers that follow summarise a health technol-
ogy assessment (HTA) commissioned by ESSKA to inform 
development of a guideline on the use of allografts in the 
knee. The aim was to assess the cost-effectiveness of allo-
grafts for various indications in the knee. This article pro-
vides a brief introduction to health economics to help readers 
with the terminology and methods in the subsequent papers.
Review
HTA research addresses the following questions:
• Does it work?
• At what cost?
• Is it worth it, compared to other possible uses of funds?
This is done to help policy-makers or commissioners of 
healthcare with a fourth question: should they provide it?
Underlying all of this is the hard reality that funds are 
always scarce and that publicly-funded health services are 
never able to fund every treatment that might do some good 
for some people. Therefore, choices have to be made about 
what to fund and what not to fund. Do policy makers fund 
osteochondral allografts or cancer drugs? The true cost of 
funding one treatment is what economists call “opportunity 
cost”—some other intervention cannot be funded.
The benefits of health care range from symptoms relieved, 
to lives prolonged (years of life gained). We capture the 
various benefits through the common currency known as 
the quality-adjusted life year (QALY), which captures both 
length of life and quality of life in one single index measure. 
One QALY = 1 year of perfect life. This makes it possible 
to compare treatments that prolong lives, with treatments 
that do not affect length of life, but improve the quality of 
life. Some treatments affect both the length and the qual-
ity of life. For example, some cancer drugs will prolong 
life, even if only for a few months, but may have unpleasant 
side-effects that reduce quality of life. Therefore, the QALYs 
gained will be less than life years gained.
If someone with a painful knee has quality of life reduced 
by 20%—a “utility” reduction of 0.2 on a scale of 0–1.0, 
where 0 is dead and 1.0 is perfect health—then, each year of 
life is worth only 0.8 QALYs. If an intervention removes or 
reduces the knee pain that increases quality of life and leads 
to an increase in QALYs. For example, clinical success and 
failure 5 years after autologous chondrocyte implantation 
(ACI) compared with microfracture were evaluated. Success 
after ACI led to an increase in utility to 0.817, compared 
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to a baseline utility score of 0.654, which equates to 0.815 
QALYs over 5 years [5].
If our patient has knee pain sufficient to reduce quality of 
life by 20%, for 10 years, that is a loss of 2.0 QALYs. If an 
intervention restores utility to normal, we gain 2 QALYs. 
Based on the cost of the intervention and all other associated 
costs and savings, we can then estimate the cost per QALY.
Health care costs should include all costs and savings. 
Costs include:
• The costs of assessment and treatment.
• The costs of any adverse effects.
• The costs of rehabilitation or other follow-up.
Treatment costs need to include all the costs of provid-
ing it. Therefore, the costs of an orthopaedic operation 
include not just the theatre and ward staff costs, but all the 
costs required to support that operation, including medical 
records, reception staff, overheads (i.e., heating, lighting, 
and maintenance), finance staff and personnel department 
costs, and so on. All these costs have to be recovered by 
hospitals in the charges they make for each case. Private 
hospitals may add on a bit to pay shareholders.
Health care savings include:
• The costs of conservative care avoided, such as analge-
sics and physiotherapy, or aids to mobility. These may be 
considerable over years. Some patients may incur pain 
that requires powerful pain killers, and addiction can 
occur.
• The costs of joint replacement if that can be avoided or 
postponed. Note that postponing a first knee arthroplasty 
may mean that a more expensive revision arthroplasty 
may never be required.
One issue that we have to take into account is discount-
ing [9]. This involves adjusting future costs and benefits to 
current values. It is based on the principle that £1000 or 
$1000 is valued more highly if received now, than in the 
future. The UK Government applies a 3.5% discount rate to 
future costs and benefits. Therefore, £1000 now is valued 
at £965 in 1 year time. This has implications for interven-
tions that lead to future costs avoided. For example, if a 
knee replacement costs £6000 today, the discounted cost is 
£4201 at 10 years and £3516 at 15 years. Therefore, if the 
intervention now leads to knee replacement avoided in 10 
years, the savings are only assessed to be £4201. However, 
discounting can also support interventions that postpone 
knee replacements—if an intervention now postpones future 
knee replacement from 10 to 15 years that equates to a sav-
ing of £4201–£3516 = £658. In cost-effectiveness analysis, 
the future saving reduces the current cost of the intervention 
by £658.
Other countries apply different discount rates, and some-
times, the rates differ for costs and outcomes, for example, 
6% for costs and 1.5% for benefits.
Discounting has been hotly debated, with some arguing 
that costs should be discounted but benefits not, but in prac-
tice, decision-making processes are based on discount rates 
set by governments. Discounting may disadvantage interven-
tions that prevent future problems, such as intensive diabetes 
treatment to prevent renal failure in 20 year time.
The cost per QALY that is considered affordable vari-
ous amongst countries. In the UK, the National Institute for 
Health and Care Excellence (NICE) regards anything under 
£20,000 per QALY as acceptable, and will also consider 
costs per QALY in the £20,000–£30,000, depending on the 
strength of evidence [4]. In some circumstances, NICE will 
accept a much higher cost per QALY, but so far, none of 
those have been in orthopaedics. Therefore, for our patient 
with the 20% reduction in quality of life for 10 years, NICE 
would consider that an investment of £40,000–£60,000 
would be justified to restore full quality of life, even without 
considering possible future savings.
There are also costs and savings for patients. These may 
include monetary costs such as loss of income from time 
of work. Economic analysis may note such costs, but they 
are often not included in cost-effectiveness analysis, as only 
costs incurred by the health care service are assessed. How-
ever, non-monetary costs such as inability to participate in 
normal activities can be picked up by quality-of-life scores.
A common problem in orthopaedic studies is that many 
of the outcome measures used such as Knee injury and 
Osteoarthritis Outcome Score (KOOS) [10] or the Western 
Ontario Meniscal Evaluation Tool (WOMET) [6] do not 
convert to a generic utility score such as the EQ-5D [3] or 
SF-6D [2]. We need the “common currency” of utility scores 
that can measure quality of life across a range of conditions 
or disease, to derive QALYs. If we have to decide whether to 
spend £500,000 on orthopaedics or cancer, we need to know 
how many QALYs we can get from each of those. We need 
the utility measure, so that we can compare the health gains 
from improving quality of life by orthopaedic interventions, 
with life years gained from cancer care (while adjusting for 
quality-of-life reductions from side-effects).
Some clinical scores such as Western Ontario and 
McMaster Universities Osteoarthritis Index (WOMAC) [7] 
have been mapped to the EQ-5D to generate utility scores 
[1, 11, 12], but it would be much better if future orthopae-
dic studies included a generic utility measure such as the 
EQ-5D. This would make it easier to do cost-effectiveness 
analysis in orthopaedics and might strengthen orthopaedic 
bids in the competition for limited health care funds.
However, we do need condition or disease-specific out-
comes measures as well, since they may be more sensitive 
to changes that matter to patients. Not every change can be 
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quantified in the EQ-5D. For example, an individual may 
score well on EQ-5D despite restriction of activities that 
were previously enjoyed, but not regarded by policy makers 
as an essential part of activities of daily living.
Not all linear changes on clinical scores will have the 
same effects on quality of life. For example, in macular eye 
disease, there may be a series of equal deteriorations in vis-
ual acuity, but the step that stops people driving has more 
impact than most.
Another issue for cost-effectiveness analysis is that trials, 
and other studies needs to provide data on effect size. It is 
not enough to say “Treatment A was better than treatment 
B, p < 0.01”—we need to know how much better treatment 
A was than treatment B. Some statistically significant dif-
ferences may be clinically and economically insignificant. 
Sometimes, a difference, which meets the minimally sig-
nificant clinical difference threshold, may be economically 
insignificant.
Not all effects, good or bad, can be precisely quantified. 
However, they can be taken account of by applying a bit of 
judgment in the appraisal process. One author (NW) of this 
article was involved in a NICE appraisal of insulin pumps, 
which can make management of diabetes easier in children. 
One effect is that parental quality of life may be improved. 
Parents, especially mothers, may need to be less “on call” 
for problems at school and this can affect their employment. 
NICE noted that.
Uncertainties are common because of lack of data. For 
example, many studies of knee cartilage repair procedures 
do not have long enough follow-up data to assess impact 
on knee replacement, or the numbers with long follow-up 
may be small. In cost-effectiveness analysis, uncertainties 
are addressed by “sensitivity analysis”. A “base case” is cre-
ated using the likeliest values and then the effect of varying 
the modelling assumptions is tested by applying higher or 
lower values instead. This can be useful for identifying the 
factors with the greatest effect, and those with little effect.
Cost-effectiveness of a procedure may vary amongst 
patients, according to patient characteristics. For example, a 
previous health technology assessment report found that the 
cost-effectiveness of autologous chondrocyte implantation 
was better amongst patients who had not had any previous 
repair attempts that damaged the subchondral bone [8]. The 
cost per QALY also increased according to Kellgren–Law-
rence grade of osteoarthritic change.
The reality of savings needs to be considered. A new ver-
sion of an operation may take 10 min less operating time, 
but unless that means that more operations can be done in a 
theatre session, or that staff hours can be reduced, there will 
be no real savings. Similarly, if the new procedure reduces 
length of hospital stay, there will be no savings unless staff-
ing levels are reduced. Indeed, there may be an increase in 
costs if the capacity saved is used for additional cases. This 
may be good for patients, but a problem for the hospital 
finance directors.
Unlike drugs, devices or procedures evolve over time, and 
the only long-term results may be from superseded versions. 
The base–case analysis could assume that newer versions are 
as good, but then, we can explore various sensitivity analy-
ses, assuming that the latest version is 10% better or 20% 
better, to see what that does to the cost per QALY.
Conclusion
HTA aims to aid decision-making by those who make deci-
sions on allocation of funds, but can also inform clinicians 
and support bids for funding of future services. As will be 
seen in an accompanying article, osteochondral allograft-
ing for people with osteochondral defects has a remarkably 
low cost per QALY, so would be regarded as highly cost-
effective by bodies such as NICE.
Acknowledgements We thank those who attended the ESSKA work-
shop on allografts in Glasgow on May 9th 2018, for useful discussions.
Author contributions NW and HM both contributed to this article.
Funding None.
Compliance with ethical standards 
Conflict of interest The authors declare no competing financial inter-
est.
Ethical approval This article did not involve any human research par-
ticipants.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Barton GR, Sach TH, Jenkinson C, Avery AJ, Doherty M, Muir 
KR (2008) Do estimates of cost-utility based on the EQ-5D differ 
from those based on the mapping of utility scores? Health Qual 
Life Outc 6(no pagination):51
 2. Brazier J, Roberts J, Deverill M (2002) The estimation of a pref-
erence-based measure of health from the SF-36. J Health Econ 
21:271–292
 3. Brooks R (1996) EuroQol: the current state of play. Health Policy 
37:53–72
 4. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S 
et al (2015) Methods for the estimation of the National Institute 
 Knee Surgery, Sports Traumatology, Arthroscopy
1 3
for Health and Care Excellence cost-effectiveness threshold. 
Health Technol Assess 19:1–503
 5. Gerlier L, Lamotte M, Wille M, Kreuz PC, Vanlauwe J, Dubois D 
et al (2010) The cost utility of autologous chondrocytes implan-
tation using ChondroCelect(R) in symptomatic knee cartilage 
lesions in Belgium. Pharmacoeconomics 28:1129–1146
 6. Kirkley A, Griffin S, Whelan D (2007) The development and 
validation of a quality of life-measurement tool for patients with 
meniscal pathology: the Western Ontario Meniscal Evaluation 
Tool (WOMET). Clin J Sport Med 17:349–356
 7. McConnell S, Kolopack P, Davis AM (2001) The Western Ontario 
and McMaster Universities Osteoarthritis Index (WOMAC): a 
review of its utility and measurement properties. Arthritis Rheum 
45:453–461
 8. Mistry H, Connock M, Pink J, Shyangdan D, Clar C, Royle P et al 
(2017) Autologous chondrocyte implantation in the knee: sys-
tematic review and economic evaluation. Health Technol Assess 
21:1–294
 9. National Institute for Health and Care Excellence (2013) Guide to 
the methods of technology appraisal 2013: process and methods 
[PMG9]. https ://www.nice.org.uk/proce ss/pmg9/chapt er/forew 
ord. Accessed 4 Dec 2018
 10. Roos H, Lauren M, Adalberth T, Roos EM, Jonsson K, Lohm-
ander LS (1998) Knee osteoarthritis after meniscectomy: preva-
lence of radiographic changes after twenty-one years, compared 
with matched controls. Arthritis Rheum 41:687–693
 11. Wailoo A, Hernandez Alava M, Escobar Martinez A (2014) Mod-
elling the relationship between the WOMAC Osteoarthritis Index 
and EQ-5D. Health Qual Life Outc 12:37
 12. Xie F, Pullenayegum EM, Li SC, Hopkins R, Thumboo J, Lo NN 
(2010) Use of a disease-specific instrument in economic evalu-
ations: mapping WOMAC onto the EQ-5D utility index. Value 
Health 13:873–878
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
